Opendata, web and dolomites

NABBA

Design and development of advanced NAnomedicines to overcome Biological BArriers and to treat severe diseases

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NABBA project word cloud

Explore the words cloud of the NABBA project. It provides you a very rough idea of what is the project "NABBA" about.

physiological    scientific    emphasis    loading    sophisticated    peculiar    platforms    acquainted    interests    technological    biological    nps    internationally    nanobiotechnology    stage    shielded    nano    crossing    cooperation    biomedical    proof    scientists    conventional    either    molecular    nanomedicine    strategies    participation    companies    np    cutting    diagnostic    nabba    benefit    mechanisms    probes    functionalization    chemistry    drugs    antibodies    proteins    pathological    techniques    characterization    edge    chemical    give    recombinant    pharmacokinetics    expertises    esr    limiting    innovative    pharmaceutics    synthetic    opportunity    assembly    therapeutics    circulation    cross    expedients    possibility    barriers    technologies    biodistribution    many    esrs    industrial    nanoparticles    network    programs    types    ruling    industries    pharmacological    academia    detection    vehicles    form    gene    therapeutic    manufacturing    train    devoted    solution    synthesis   

Project "NABBA" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA 

Organization address
address: PIAZZA DELL'ATENEO NUOVO 1
city: MILANO
postcode: 20126
website: www.unimib.it

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Project website http://www.nabbaproject.eu
 Total cost 2˙851˙274 €
 EC max contribution 2˙851˙274 € (100%)
 Programme 1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
 Code Call H2020-MSCA-ITN-2014
 Funding Scheme MSCA-ITN-ETN
 Starting year 2015
 Duration (year-month-day) from 2015-01-01   to  2019-02-28

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA IT (MILANO) coordinator 917˙551.00
2    CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS FR (PARIS) participant 525˙751.00
3    HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH DE (BRAUNSCHWEIG) participant 498˙432.00
4    UNIVERSIDAD DE SANTIAGO DE COMPOSTELA ES (SANTIAGO DE COMPOSTELA) participant 495˙745.00
5    UNIVERSITEIT UTRECHT NL (UTRECHT) participant 255˙374.00
6    ENVIROINVEST KORNYEZETVEDELMI ES BIOTECHNOLOGIAI ZARTKORUEN MUKODO RESZVENYTARASASAG HU (PECS) participant 158˙418.00
7    BIOTALENTUM TUDASFEJLESZTO KFT HU (GOEDOELLO) partner 0.00
8    EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH CH (ZUERICH) partner 0.00
9    NOVARTIS PHARMA AG CH (BASEL) partner 0.00
10    SYLENTIS SAU ES (Madrid) partner 0.00

Map

 Project objective

Many therapeutic targets are shielded behind biological barriers, limiting the possibility to reach them with conventional drugs or diagnostic probes. Biological barriers are even more problematic for most biological pharmaceutics, such as recombinant proteins, antibodies and gene therapeutics. The most promising solution to this challenge is the use of nano-vehicles for specific targeting and delivery. The aim of NABBA is to form European early stage researchers (ESR) with cutting-edge scientific knowledge in the field of nanoparticles (NP) for biomedical application, able to cross biological barriers. For this aim the project will train ESRs, focusing on key aspects of nanobiotechnology: (i) design and chemical synthesis of different types of NPs, (ii) related techniques of detection and characterization, (iii) strategies of loading, targeting and delivery of drugs or diagnostic probes; (iv) proof of principle of pharmacological activity including pharmacokinetics and biodistribution. As a peculiar feature of NABBA, strong emphasis will be devoted to molecular mechanisms ruling biological barriers under physiological and pathological conditions, in order to develop novel nano-technological expedients for their crossing. Strong emphasis will be devoted to advanced chemistry issues, enabling new synthetic strategies either for NP assembly or functionalization. Different biological barriers will be addressed. ESRs will strongly benefit from a network of internationally recognized scientists in the field of chemistry, nanobiotechnology and nanomedicine, and the participation of companies with relevant interests and expertises in the field. The planned cooperation programs between Academia and Industries will allow the circulation of ESRs and this will give them the opportunity for to get acquainted with the most advanced research in the field, the most sophisticated technologies and the most advanced Industrial manufacturing platforms and innovative strategies.

 Deliverables

List of deliverables.
Website Websites, patent fillings, videos etc. 2019-09-06 10:41:36
ESRs representative Other 2019-09-06 10:41:36

Take a look to the deliverables list in detail:  detailed list of NABBA deliverables.

 Publications

year authors and title journal last update
List of publications.
2018 Duy-Khiet Ho, Ana Costa, Chiara De Rossi, Cristiane de Souza Carvalho-Wodarz, Brigitta Loretz, Claus-Michael Lehr
Polysaccharide Submicrocarrier for Improved Pulmonary Delivery of Poorly Soluble Anti-infective Ciprofloxacin: Preparation, Characterization, and Influence of Size on Cellular Uptake
published pages: 1081-1096, ISSN: 1543-8384, DOI: 10.1021/acs.molpharmaceut.7b00967
Molecular Pharmaceutics 15/3 2019-09-06
2018 Alysia Cox, Patrizia Andreozzi, Roberta Dal Magro, Fabio Fiordaliso, Alessandro Corbelli, Laura Talamini, Clizia Chinello, Francesca Raimondo, Fulvio Magni, Maria Tringali, Silke Krol, Paulo Jacob Silva, Francesco Stellacci, Massimo Masserini, Francesca Re
Evolution of Nanoparticle Protein Corona across the Blood–Brain Barrier
published pages: 7292-7300, ISSN: 1936-0851, DOI: 10.1021/acsnano.8b03500
ACS Nano 12/7 2019-09-06
2016 Anshuman Dasgupta, Mengjiao Liu, Tarun Ojha, Gert Storm, Fabian Kiessling, Twan Lammers
Ultrasound-mediated drug delivery to the brain: principles, progress and prospects
published pages: 41-48, ISSN: 1740-6749, DOI: 10.1016/j.ddtec.2016.07.007
Drug Discovery Today: Technologies 20 2019-09-06
2018 Josu Andrieu, Francesca Re, Laura Russo, Francesco Nicotra
Phage-displayed peptides targeting specific tissues and organs
published pages: 1-11, ISSN: 1061-186X, DOI: 10.1080/1061186x.2018.1531419
Journal of Drug Targeting 2019-09-06
2017 Irene Santalices, Andrea Gonella, Dolores Torres, María José Alonso
Advances on the formulation of proteins using nanotechnologies
published pages: 155-180, ISSN: 1773-2247, DOI: 10.1016/j.jddst.2017.06.018
Journal of Drug Delivery Science and Technology 42 2019-09-06
2018 Daniele Vinciguerra, Johanna Tran, Julien Nicolas
Telechelic polymers from reversible-deactivation radical polymerization for biomedical applications
published pages: 228-240, ISSN: 1359-7345, DOI: 10.1039/c7cc08544c
Chemical Communications 54/3 2019-09-06
2018 Duy-Khiet Ho, Sarah Frisch, Alexander Biehl, Emmanuel Terriac, Chiara De Rossi, Konrad Schwarzkopf, Franziska Lautenschläger, Brigitta Loretz, Xabier Murgia, Claus-Michael Lehr
Farnesylated Glycol Chitosan as a Platform for Drug Delivery: Synthesis, Characterization, and Investigation of Mucus–Particle Interactions
published pages: 3489-3501, ISSN: 1525-7797, DOI: 10.1021/acs.biomac.8b00795
Biomacromolecules 19/8 2019-09-06
2018 Hanzey Yasar, Duy-Khiet Ho, Chiara De Rossi, Jennifer Herrmann, Sarah Gordon, Brigitta Loretz, Claus-Michael Lehr
Starch-Chitosan Polyplexes: A Versatile Carrier System for Anti-Infectives and Gene Delivery
published pages: 252, ISSN: 2073-4360, DOI: 10.3390/polym10030252
Polymers 10/3 2019-09-06
2018 Gianpiero Lazzari, Valérie Nicolas, Michiya Matsusaki, Mitsuru Akashi, Patrick Couvreur, Simona Mura
Multicellular spheroid based on a triple co-culture: A novel 3D model to mimic pancreatic tumor complexity
published pages: 296-307, ISSN: 1742-7061, DOI: 10.1016/j.actbio.2018.08.008
Acta Biomaterialia 78 2019-09-06
2018 Daniele Vinciguerra, Stéphanie Denis, Julie Mougin, Merel Jacobs, Yohann Guillaneuf, Simona Mura, Patrick Couvreur, Julien Nicolas
A facile route to heterotelechelic polymer prodrug nanoparticles for imaging, drug delivery and combination therapy
published pages: 425-438, ISSN: 0168-3659, DOI: 10.1016/j.jconrel.2018.08.013
Journal of Controlled Release 286 2019-09-06
2017 Qingxue Sun, Tarun Ojha, Fabian Kiessling, Twan Lammers, Yang Shi
Enhancing Tumor Penetration of Nanomedicines
published pages: 1449-1459, ISSN: 1525-7797, DOI: 10.1021/acs.biomac.7b00068
Biomacromolecules 18/5 2019-09-06
2016 Okan Tezcan, Tarun Ojha, Gert Storm, Fabian Kiessling, Twan Lammers
Targeting cellular and microenvironmental multidrug resistance
published pages: 1199-1202, ISSN: 1742-5247, DOI: 10.1080/17425247.2016.1214570
Expert Opinion on Drug Delivery 13/9 2019-09-06
2016 Benjamin Theek, Maike Baues, Tarun Ojha, Diana Möckel, Seena Koyadan Veettil, Julia Steitz, Louis van Bloois, Gert Storm, Fabian Kiessling, Twan Lammers
Sonoporation enhances liposome accumulation and penetration in tumors with low EPR
published pages: 77-85, ISSN: 0168-3659, DOI: 10.1016/j.jconrel.2016.02.021
Journal of Controlled Release 231 2019-09-06
2016 Miriam Colombo, Luisa Fiandra, Giulia Alessio, Serena Mazzucchelli, Manuela Nebuloni, Clara De Palma, Karsten Kantner, Beatriz Pelaz, Rany Rotem, Fabio Corsi, Wolfgang J. Parak, Davide Prosperi
Tumour homing and therapeutic effect of colloidal nanoparticles depend on the number of attached antibodies
published pages: 13818, ISSN: 2041-1723, DOI: 10.1038/ncomms13818
Nature Communications 7 2019-09-06
2017 Tarun Ojha, Vertika Pathak, Yang Shi, Wim E. Hennink, Chrit T.W. Moonen, Gert Storm, Fabian Kiessling, Twan Lammers
Pharmacological and physical vessel modulation strategies to improve EPR-mediated drug targeting to tumors
published pages: , ISSN: 0169-409X, DOI: 10.1016/j.addr.2017.07.007
Advanced Drug Delivery Reviews 2019-09-06

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NABBA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NABBA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.1.)

BIGMATH (2018)

Big Data Challenges for Mathematics

Read More  

DISTINCT (2019)

Dementia: Intersectorial Strategy for Training and Innovation Network for Current Technology (DISTINCT)

Read More  

POLISS (2019)

Policies for Smart Specialisation

Read More